What is DSIP, and why are people interested in it?

DSIP stands for delta sleep-inducing peptide. It is a chain of nine amino acids, also called emideltide. Researchers first described its isolation and synthesis in rabbit experiments in the 1970s. The name came from changes in slow brain-wave activity in that research. Original 1977 study.

That gave researchers a reason to ask whether it could help disturbed sleep. It did not establish that taking DSIP reliably produces deeper or more restorative sleep in people. The research question and the name should not be mistaken for a demonstrated treatment effect.

What have human sleep studies found?

Several small human reports exist. They do not all point in the same direction, and the way each study was conducted matters.

A favorable report in 14 people. A 1987 study of people with chronic insomnia reported improved sleep and daytime functioning after a week of intravenous DSIP. However, there was no concurrent placebo-treatment group. The study used baseline and post-treatment placebo nights, with additional comparisons to healthy external controls. This limits how confidently the improvement can be attributed to DSIP. 1987 report; FDA appraisal of the study design.

A different 1987 study found little clinical benefit. Monti and colleagues used a double-blind crossover design, so participants received DSIP and placebo in different periods. Several sleep measures did not improve significantly over placebo. Some differences in stage-2 and non-REM sleep were already present at baseline, and slow-wave sleep did not change. The authors judged the improvement to have little clinical significance. Crossover study.

A 1992 trial found weak effects. In 16 people with chronic insomnia, DSIP was associated with higher measured sleep efficiency and shorter sleep latency than placebo. However, the authors said the effects were weak and might partly reflect an incidental change in the placebo group. Subjective sleep quality did not improve. They concluded that short-term treatment was unlikely to provide major therapeutic benefit. 1992 trial.

These findings leave room for further investigation, but they do not establish a reliable insomnia treatment. A positive small study should be read alongside the less favorable studies, not on its own.

Does the research end with those insomnia studies?

No. Other human work includes a 2009 study in 24 women undergoing anaesthesia. DSIP increased heart rate and, at one tested level, reduced delta activity and lightened measured anaesthetic depth. This was not an insomnia trial, so it cannot answer whether DSIP improves ordinary sleep. It does show why the peptide's effects cannot be reduced to “more deep sleep.” Anaesthesia study.

Animal research has also continued. A 2021 rat stroke experiment reported improved motor performance on one test, while the difference in brain-infarct size was not statistically significant. That does not establish stroke recovery or sleep benefit in people. Rat study.

We have not established why larger, decisive insomnia trials remain limited. Claims that research stopped because nobody could patent DSIP or because there was no sponsor would go beyond the evidence reviewed here.

What remains uncertain about safety and everyday use?

The sleep studies discussed above used intravenous administration in research settings. They do not establish the effectiveness or safety of a product injected under the skin at home. The 2009 heart-rate findings also make blanket claims of harmlessness inappropriate.

FDA's July 2026 evaluation found insufficient safety information for the proposed subcutaneous route. It also noted that emideltide free base and acetate were not components of an FDA-approved drug. A compounding review is not drug approval or proof that a particular product is suitable for a patient. FDA evaluation.

FDA's current safety page identifies possible immune-reaction and peptide-quality concerns. The remaining uncertainties include longer-term effects, interactions and whether a specific preparation matches the material used in research. FDA safety information.

How should someone judge a report of better sleep?

A report of feeling more rested is worth understanding. Useful details include changes in time to fall asleep, waking during the night, daytime function and other treatments or habits. Those observations can guide a conversation, but they cannot establish that DSIP caused the change or predict another person's response.

Persistent insomnia also deserves treatment in its own right. The American Academy of Sleep Medicine strongly recommends multicomponent cognitive behavioral therapy for insomnia, or CBT-I, for adults with chronic insomnia. Its guidance advises against using sleep hygiene alone as the treatment. That is more substantial than simply being told to improve a bedtime routine. AASM guideline.

What should someone ask before considering DSIP?

  • What is causing my sleep problem, and does the proposed treatment address it?
  • Which human results support this product, route and intended outcome?
  • What safety information is missing, and could it interact with my other care?
  • Have established treatments such as CBT-I been considered?
  • How would we track meaningful improvement in sleep and daytime function, and when would we stop?

DSIP deserves an accurate explanation. There is human research, including some encouraging observations, but the mixed findings and study limitations matter. A name associated with deep sleep cannot do the work of a well-designed clinical trial.

Questions people ask

Does DSIP reliably increase deep sleep?

That has not been established. Small insomnia studies produced mixed findings. In a 1987 crossover study, slow-wave sleep did not change, and the authors judged the overall sleep improvement to have little clinical significance.

Were there only two human studies?

No. The published record includes additional insomnia reports and human research in other settings. A 2009 anaesthesia study is one example, but it does not demonstrate a benefit for insomnia.

Is DSIP proven safe for home injection?

No. Intravenous research does not establish safety for subcutaneous use. FDA identified insufficient safety information for the proposed subcutaneous route, and longer-term risks and product-specific questions remain.

The evidence

Selected original studies and official sources. Related research is searchable on our Science page.

PRECLINICALSchoenenberger and Monnier. Characterization of a delta-electroencephalogram (delta-sleep)-inducing peptide (1977). PubMed 265572
HUMAN STUDYSchneider-Helmert. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia (1987). PubMed 3622582
CONTROLLED TRIALMonti et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs (1987). PubMed 3583493
CONTROLLED TRIALBes et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study (1992). PubMed 1299794
HUMAN STUDYPomfrett et al. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia (2009). PubMed 19142086
PRECLINICALTukhovskaya et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke (2021). PubMed 34500605
REGULATORY REVIEWFDA. Emideltide-related bulk drug substances, July 2026 briefing. Read source
REGULATORY GUIDANCEFDA. Bulk drug substances that may present significant safety risks. Read source
GUIDELINEEdinger et al. AASM guideline on behavioral and psychological treatments for chronic insomnia (2021). Read source

Sources checked November 5, 2026. Original study abstracts and FDA's full appraisal were checked; paywalled full texts of the older insomnia trials were not independently available. The examples above are not a claim to catalogue every human DSIP study. No article-specific medical review is claimed.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. DSIP (Delta Sleep-Inducing Peptide) is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.